
FDA Guidance & Highlights, annotated for ultra-rare developers
A focused FDA guidance package with highlights and annotations for ultra-rare developers planning an N-of-1 strategy.
more
- 1-1 FDA Highlights.pdf
- 1-2 FDA Guidance: CMC Flexibilities for CGT BLA - May2026.pdf
- 1-3 FDA Guidance: FAQs-Developing Potential CGT Products-Aug2026.pdf
- 1-4 FDA Guidance: Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions - Feb2026.pdf
Annotated FDA guidance set for ultra-rare developers, designed to support faster review of CGT strategy, CMC positioning, and individualized therapy considerations.


